34 results about "TWEAK RECEPTOR" patented technology

The present application relates to a GLP-1 receptor agonist, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a method for treating or preventing a GLP-1 receptor-mediated disease or disorder or regulating a GLP-1 receptor.

The invention relates to the field of cosmetics, in particular to a sialic acid composition with an acne removing effect, a preparation method of the sialic acid composition and cosmetics. The composition is prepared from 8%-20% of sialic acid, 10%-25% of ectoine, 5%-15% of a humectant, 0.1%-1% of a thickening agent, 0.05%-0.5% of a pH regulator and the balance of water. Cubilose acid can promote collagen synthesis, repair damaged skin barrier and reduce inflammatory response caused by external stimulation, and acne generation is inhibited from acne inducement; meanwhile, the sialic acid can inhibit release of proinflammatory factors such as TNF-alpha and IL-6 by adjusting a TLR receptor signal channel, red and swollen pox is relieved, and the generated pox is inhibited from the aspect of inhibiting inflammation; the sialic acid is non-irritant, and can slightly promote cutin renewal under high concentration, so that the problems of skin desquamation, sensitivity and the like caused by barrier injury can be effectively avoided. Ectoin is compounded, so that the Ectoin and sialic acid can generate a synergistic interaction effect.

The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and / or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and / or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and / or an agent that treats, ameliorates, and / or prevents one or more virus infection symptoms and / or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors / antagonists that cause and / or trigger ER stress and / or autophagy are useful within the methods of the disclosure.

Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

The present disclosure relates generally to adenosine receptor modulator compounds of formula (I), and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of A2B adenosine receptor activity.

Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a mutant Notch NRR (Negative Regulatory Region). Another aspect of the invention relates to a protease-dependent synthetic protein. Engineered cells comprising the synthetic protein are additionally described herein.

The present invention discloses an aryl group-containing amine compound, its preparation method, and use. The aryl group-containing amine compound is represented by formula (I), and has the function of regulating NMDA receptor and / or monoamine transporter and / or sigma receptor activity, and can be used to prepare a medicament for treating and / or preventing diseases associated with NMDA receptors and / or monoamine transporters and / or sigma receptors, particularly central nervous system diseases. JPEG2025538201000350.jpg4951

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.

The present invention relates to compounds that inhibit the toxic activity of extrasynaptic NMDA receptors, particularly by inhibiting the formation of the NMDA receptor / TRPM4 complex. In particular, the present invention relates to diamine compounds according to general formula I and their use in medicine, especially in the treatment of neurological disorders such as neurodegenerative disorders.

This document provides compounds and their compositions for modulating the S1P5 receptor. In some cases, the compounds and compositions are provided for the treatment of neurological diseases.

The present application relates to a novel GLP-1 receptor agonist, which is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing GLP-1 receptor mediated diseases or disorders or modulating GLP-1 receptor. Formula (I).

The present application relates to a GLP-1 receptor agonist, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a method for treating or preventing a GLP-1 receptor-mediated disease or disorder or regulating a GLP-1 receptor.

The present invention relates to compounds inhibiting the toxic activity of extrasynaptic NMDA receptors, in particular by inhibiting the formation of NMDA receptor / TRPM4 complexes. In particular, the present invention relates to diamine-based compounds according to general formula I and their use in medicine, in particular for treating neurological diseases such as neurodegenerative diseases.

The invention relates to the technical field of microorganisms, in particular to lactobacillus kefir and application thereof in the aspect of regulating animal immune functions. The invention provides Kefir lactobacillus brachyphyllum Fanghua, and the preservation number of the Kefir lactobacillus brachyphyllum Fanghua is CGMCC (China General Microbiological Culture Collection Center) NO.27733 Research finds that compared with an immunosuppression model mouse constructed by using hydrocortisone, the weight of immune organs thymus and spleen can be increased, the number of peripheral blood leucocytes can be increased, and immune cell composition and expression of inflammation-related genes can be changed when the mouse is fed with the Lactobacillus kefir Fanghua. Besides, after the excrement of the aged mice fed with the lactobacillus kefir Fanghua is transplanted to the sterile mice, compared with excrement only transplanted to the aged mice, the content of dendritic cells in the spleen of the receptor mice can be reduced, differentiation of helper T cells can be inhibited, expression of inflammation-related genes can be remarkably reduced, and the inflammation-related effects can be improved. Further, the immune inflammatory response of the receptor mouse is regulated.

The present application relates to a GLP-1 receptor agonist, a pharmaceutically acceptable salt thereof, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a method thereof for treating or preventing a GLP-1 receptor mediated disease or disorder or modulating a GLP-1 receptor. # imgabs0 #

The present invention relates to compounds useful in the modulation of the sigma-1 receptor (S1R). The present invention also relates to the use of these compounds in the treatment of sigma-1 receptor (S1R) associated diseases and disorders, for instance, diseases and disorders associated with ER stress, and diseases and disorders which would benefit from sigma-1 receptor (S1R) activation.

The disclosures herein relate to novel compounds of formulawherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The present application relates to a heterocyclic GLP-1 derivative, a pharmaceutically acceptable salt thereof, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a GLP-1 receptor mediated disease or disorder or modulating a GLP-1 receptor thereof. # imgabs0 #

Provided are methods of modifying the solubility properties of individual peptides and sets of peptides of which an example embodiment includes sets of overlapping peptides prepared to be suitable for use as vaccines to modulate the immune responses of recipients. The peptides are modified to have the requisite solubility properties for tissue delivery by precipitation without extraneous binding and modification of antigenicity. According to example embodiments. the modified peptides are suitable to be used in TDBP / VDBP methods. Also provided herein are the solubility-modified peptides themselves and kits that include them. Further provided are methods of administering solubility-modified peptides with the requisite solubility properties for tissue delivery by precipitation.

Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a mutant Notch NRR (Negative Regulatory Region). Another aspect of the invention relates to a protease-dependent synthetic protein. Engineered cells comprising the synthetic protein are additionally described herein.

Provided is a drug for preventing, alleviating or treating adhesion and a use thereof. A fibroblast which has been subjected to external stimulation in a body cavity contains an activated negative regulatory receptor PEAR1. The deletion of the fibroblast PEAR1 can significantly promote in vivo mucosal adhesion formation. A PEAR1 agonist can specifically inhibit fibroblast activation, synthesize an extracellular matrix, and ameliorate the adhesion lesion. By administering the PEAR1 agonist, the formation of adhesion can be effectively prevented. Also provided is a PEAR1 agonistic antibody that does not affect the repair and healing of normal tissue and does not cause the tissue to be in an anoxic state. Moreover, the antibody drug has a long half-life, is easily diffused, has few side effects, and has a convenient route of administration.

The present disclosure relates to compounds that may be used to modulate the activity of a σ2R / TMEM97 receptor. The compounds may be further defined by the formula: (IA), (IB), or (IC) wherein the variables are as described herein. The present disclosure also provides pharmaceutical compositions of the compounds. Also, provided herein are methods of using the compounds in the treatment of neurodegenerative diseases or disorders among other indications.

Provided herein are modified forms of Conantokin peptides, including, modified Con-P peptides, nucleic acids encoding the same and compositions thereof. Further provided are nucleic acid molecules encoding for chimeric modified conantokin polypeptides to be expressed in or on a membrane of a target cells, compositions comprising the same and uses thereof for treating various neurodegenerative conditions.

The present invention provides peptide conjugates comprising peptides that modulate the GLP-2 receptor. The peptide conjugates can be used to treat conditions that respond to modulation of the GLP-2 receptor. The present invention also provides stapled GLP-2 peptide conjugates.

This disclosure provides antibodies that bind to IL-25 and their antibody fragments. The disclosed antibodies and their antibody fragments can modulate the biological activity of the IL-25 / IL-25 receptor signaling axis and are therefore useful in the treatment of type 2 inflammatory diseases, autoimmune diseases, allergic disorders, or cancer.

The present disclosure provides antibodies and antibody fragments thereof that bind IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate the biological activity of the IL-23 receptor signaling axis and are therefore useful for treating immune-mediated inflammatory diseases.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for 5-hydroxytryptamine (5-HT3) receptor modulation using a 5-HT3 receptor partial agonist, a 5-HT3 receptor antagonist or a Glucagon-like peptide-1 (GLP-1) receptor agonist, wherein optionally the GLP-1 receptor agonist is liraglutide, for the treatment of intestinal and other diseases. In alternative embodiments, provided are therapeutic combinations and methods of use of a 5-HT3 receptor modulator, a 5-HT3 receptor partial agonist, a 5-HT3 receptor antagonist, or a Glucagon-like peptide-1 (GLP-1) receptor agonist, wherein optionally the GLP-1 receptor agonist is liraglutide, for treating irritable bowel syndrome (IBS), carcinoid syndrome, Low anterior resection syndrome (LARS), Bile Acid Diarrhea (BAD), ileal resection diarrhea, diarrhea associated with ileoanal anastomosis, adverse reactions related to Glucagon-Like Peptide-1(GLP-1) or dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) modulator therapy, and gastrointestinal infections, and other diseases.

The present application is directed, in part, to compounds, and / or pharmaceutically acceptable salts or solvates thereof, and / or pharmaceutical compositions thereof, for modulating the activity of Sigma1 receptor. The present application is further directed, in part, to methods for treating and / or preventing cancer using compounds disclosed herein, and / or pharmaceutically acceptable salts or solvates thereof, and / or pharmaceutical compositions thereof.